Overview

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Phase:
Phase 1
Details
Lead Sponsor:
PYC Therapeutics